Discover management strategies for alopecia areata, from anti-inflammatory diets to stress reduction techniques that can help ...

While similarities exist between types of alopecia, distinct clinical characteristics help patients & physicians ...

The Food and Drug Administration (FDA) has granted Fast Track designation to bempikibart for the treatment of alopecia areata (AA).

Prompt diagnosis and treatment are needed to help thwart continued ... the pathogenesis of these diseases and primary cicatricial alopecia in general (Ross et al., 2005). In 2005, researchers ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

About 700,000 people in the United States live with alopecia areata 1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing ...

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported ...

As they are used to treat alopecia areata (AA) (at least in adults), all ... the responsibility always lies with the corticosteroid treatment indicated by the dermatologist. In this paper, the ...

has granted Fast Track designation to bempikibart for the treatment of Alopecia Areata (AA), an autoimmune disease that attacks hair follicles causing patchy hair loss. Fast Track is a process ...

Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program.